PLYMOUTH MEETING, Pa.,
July 1, 2014 /PRNewswire/
-- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced that
it has been added to the Russell Global, Russell 2000 and Russell
Microcap Indexes. Each June, Russell realigns its family of global
equity indexes to reflect market changes in the past year.
Approximately $5.2 trillion in assets
are currently benchmarked to Russell Indexes.
Many investors use mutual funds or exchange-traded funds based
on the Russell Indexes as a way to gain exposure to certain
portions of the U.S. stock market. Russell's index design has led
to more assets benchmarked to its U.S. index family than all other
U.S. equity indexes combined. The most well-known index of the
series is the Russell 2000, which tracks US small-cap stocks.
Inclusion in these indexes is based upon market capitalization
and other market factors relating to a company and its stock.
Membership in these indexes is updated annually and remains in
place for one year.
Dr. J. Joseph Kim, Inovio's
President and CEO, said, "We are pleased to meet the requirements
for inclusion in these Russell Indexes. This inclusion reflects
Inovio's accomplishments in advancing its promising DNA
immunotherapy science and clinical programs as well as in
partnering important products. Being part of these indexes will
increase awareness of Inovio among investors in the U.S. and
globally, and increase institutional ownership of Inovio stock
through passive index fund investments."
About Russell
Russell Investments is a global asset manager and one of only a
few firms that offers actively managed multi-asset portfolios and
services that include advice, investments and implementation.
Russell stands with institutional investors, financial advisors and
individuals working with their advisors—using the firm's core
capabilities that extend across capital market insights, manager
research, portfolio construction, portfolio implementation and
indexes to help each achieve their desired investment outcomes.
About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing vaccines to prevent and treat today's
cancers and challenging infectious diseases. Its SynCon®
DNA immunotherapies, in combination with its proprietary
electroporation delivery, are generating best-in-class immune
responses, with therapeutic T-cell responses exceeding other
technologies in terms of magnitude, breadth, and response rate.
Human data to date have shown a favorable safety profile. Inovio's
lead vaccine, a therapeutic against HPV-caused pre-cancers and
cancers, is in phase II. Other phase I and preclinical programs
target prostate, breast, and lung cancers as well as HIV,
influenza, malaria and hepatitis. Partners and collaborators
include Roche, the University of
Pennsylvania, NIH, HIV Vaccines Trial Network, National
Cancer Institute, U.S. Military HIV Research Program, US Dept. of
Homeland Security, and University of
Manitoba. More information is available at
www.inovio.com.
This press release contains certain forward-looking
statements relating to our business, including our plans to develop
electroporation-based drug and gene delivery technologies and DNA
vaccines and our capital resources. Actual events or results may
differ from the expectations set forth herein as a result of a
number of factors, including uncertainties inherent in pre-clinical
studies, clinical trials and product development programs
(including, but not limited to, the fact that pre-clinical and
clinical results referenced in this release may not be indicative
of results achievable in other trials or for other indications,
that the studies or trials may not be successful or achieve the
results desired, that pre-clinical studies and clinical trials may
not commence or be completed in the time periods anticipated, that
results from one study may not necessarily be reflected or
supported by the results of other similar studies and that results
from an animal study may not be indicative of results achievable in
human studies), the availability of funding to support continuing
research and studies in an effort to prove safety and efficacy of
electroporation technology as a delivery mechanism or develop
viable DNA immunotherapies and vaccines, the adequacy of our
capital resources, the availability or potential availability of
alternative therapies or treatments for the conditions targeted by
the company or its collaborators, including alternatives that may
be more efficacious or cost-effective than any therapy or treatment
that the company and its collaborators hope to develop, evaluation
of potential opportunities, issues involving product liability,
issues involving patents and whether they or licenses to them will
provide the company with meaningful protection from others using
the covered technologies, whether such proprietary rights are
enforceable or defensible or infringe or allegedly infringe on
rights of others or can withstand claims of invalidity and whether
the company can finance or devote other significant resources that
may be necessary to prosecute, protect or defend them, the level of
corporate expenditures, assessments of the company's technology by
potential corporate or other partners or collaborators, capital
market conditions, the impact of government healthcare proposals
and other factors set forth in our Annual Report on Form 10-K for
the year ended December 31, 2013, our
Form 10-Q for the quarter ended March 31,
2014, and other regulatory filings from time to time. There
can be no assurance that any product in Inovio's pipeline will be
successfully developed or manufactured, that final results of
clinical studies will be supportive of regulatory approvals
required to market licensed products, or that any of the
forward-looking information provided herein will be proven
accurate.
CONTACTS:
Investors: Bernie
Hertel, Inovio Pharmaceuticals, 858-410-3101,
bhertel@inovio.com
Media: Jeff Richardson, Inovio
Pharmaceuticals, 267-440-4211, jrichardson@inovio.com
Logo -
http://photos.prnewswire.com/prnh/20131118/LA18202LOGO
SOURCE Inovio Pharmaceuticals, Inc.